GHSC-PSM ARV FY2025 -FY2026 PRESOLICITATION NOTICE

SECTION 1: INTRODUCTION

With support from the U.S. President's Emergency Plan for AIDS Relief, through USAID, Chemonics International Inc. and its consortium members implements the Global Health Supply Chain Program – Procurement and Supply Management (GHSC-PSM). The purpose of GHSC-PSM is to ensure uninterrupted supplies of health commodities in support of several U.S. government-funded public health initiatives around the world. Specifically, the program provides procurement and supply chain management support to the President's Emergency Plan for AIDS Relief (PEPFAR through the supply of a wide range of health commodities, including contraceptives and condoms, essential drugs; and select commodities for HIV/AIDS malaria, maternal and child health, and infectious diseases.

Purpose. GHSC-PSM is developing a strategic sourcing plan to procure antiretroviral drugs (ARVs) for fiscal year 2025 (FY25) and fiscal year 2026 (FY26)[1]. The purpose of this presolicitation notice is to share an overview of the sourcing strategies under consideration with GHSC-PSM ARV suppliers. It also serves as an advance notice to ARV suppliers and their partners to enable them to make necessary preparations in anticipation of the forthcoming release of the Request for Proposals (RFP).

SECTION 2: OBJECTIVES

ARV Sourcing Objectives. In alignment with PEPFAR's programmatic goals of developing a more sustainable ARV supply chain, GHSC-PSM shall continue to build upon the successes of previous ARV allocation strategies, namely the D-term program and the Vendor Managed Solutions (VMS) program. Objectives being considered for the next two years include:

1) Reducing order cycle times (measured as order placement to delivery of product to country) while improving the assurance of supply for market constrained ARVs.
2) Creating strategic opportunities between ARV suppliers and PEPFAR-supported country stakeholders (government, ministries of health, other procurement entities) to achieve USAID's Private Sector Engagement Objectives.
3) Prioritizing the procurement of ARVs positioned closer to the patient.
4) Establishing a sourcing strategy that enables the procurement of TLD manufactured on the African continent in support of the PEPFAR 2030 goals.
5) Streamlining and standardizing the way we conduct business with supply partners through the automated Electronic Data Interchange (EDI).

[1] Fiscal Year (FY) 2025 is 1st October, 2024 to 30th September, 2025 and FY 2026 is 1st October, 2025 to 30th September, 2026.

PEPFAR's 2021 Private Sector Engagement policy and USAID's Private Sector Engagement Policy recognizes the importance of private sector involvement in mobilizing market-based solutions for sustainable and scalable outcomes. As a result of this policy, USAID remains interested in diversifying its partner base by including more private enterprises alongside traditional development/implementing partners.

GHSC-PSM shall continue to support these policies through the D-Term program and by extending the period of performance for the Southern Africa VMS program. In FY25 and FY26, GHSC-PSM shall actively explore increased opportunities for the downstream delivery of ARVs (delivery beyond central medical stores) and support country-specific VMS sourcing strategies. A Global RFP is planned for release in June 2024 to source ARVs from eligible ARV sources (as listed on the GHSC-QA ARV eligibility list) with the inclusion of D-TERM and VMS programs.

In 2022, PEPFAR announced ambitious targets to transition at least two million clients on first-line ARV treatments to African-made products by 2030. The regional production of HIV commodities has been identified as a critical priority in PEPFAR's five-year strategy to ensure the sustainability of the HIV/AIDS response. PEPFAR is actively exploring opportunities to enable emerging African manufacturers to scale up their operations and existing ARV manufacturers to expand operations into Africa. GHSC-PSM, in close collaboration with USAID and other program partners, has been working to develop a long-term roadmap to support this priority.

As part of our FY25 sourcing strategy, GHSC-PSM shall incorporate into our strategic framework the ability to procure a proportion of Dolutegravir/Lamivudine/Tenofovir DF 50/300/300 mg (TLD) demand from eligible sources on the African continent who offer the product at a fair market rate. The framework shall prioritize TLD that is fully manufactured on the African continent that is FDA tentative approved but shall also value FDA tentative approved products that are manufactured or packaged on the African continent (should these variations be deemed eligible for procurement). If ARV suppliers on the African continent are added to the GHSC-QA ARV eligibility list prior to the closure date of the Global RFP, they shall be considered for allocation under the full FY25 Global RFP should a bid be submitted. Should eligibility be obtained after FY25 allocations, a subsequent Regional RFP would be released.

This document provides a detailed overview and timelines of the **ARV Global RFP only**. However, when a pathway to the release of a Regional RFP strategy is identified, further details and information shall be shared through separate communications.

SECTION 3: OVERVIEW OF THE GHSC-PSM ARV GLOBAL RFP

Sourcing Strategies Under Consideration. The GHSC-PSM ARV Global RFP is considering the following strategic approaches:

- **Non-TLD ARV allocations with fixed FCA pricing**. For most ARV products listed in Annex 2, GHSC-PSM intends to establish fixed FCA prices and country allocations for an extended period of 2 years (November 2024 - November 2026). GHSC-PSM shall continue with a pre-determined allocation exercise that establishes a primary, secondary, and where applicable tertiary supplier by PEPFAR country serviced. Country specific allocations shall be established for the ten D-term countries detailed in Annex 1 and Rest of the World. Products

listed in the updated ARVs list, detailed on Annex 2, are candidates for consideration for procurement within this strategy.

- **Non-TLD ARVs sourced through open competition, with established ceiling prices for FCA.** Products under this strategy will be procured through open competition from eligible suppliers with established IDIQ contracts. ARVs listed on Annex 3 are candidates for consideration for procurement within this strategy. GHSC-PSM maintains the right to move products listed in Annex 3 to an annual allocation in FY26.

- **Eligibility to offer D-Term services and establish modified DDP/DAP fixed lane rates.** GHSC-QA shall evaluate suppliers and their proposed third-party logistics partners for eligibility to participate in the D-Term program through a separate RFP, to be released in May 2024. Any supplier currently not eligible to offer D-Term services or any existing D-Term eligible supplier interested in adding new freight partner(s) shall be required to submit proposals and adequate supporting documentation in response to the GHSC-QA RFP. Currently, GHSC-PSM and GHSC-QA do not intend to add new suppliers to the D-Term program in FY26 but reserve the option to do so.

  Consistent with the FY24 ARV strategy, GHSC-PSM intends to establish fixed DAP/DDP lane rates with eligible D-Term ARV suppliers to the ten D-Term countries listed in Annex 1 for a period of 12-months (December 2024 through November 2025)**.** The modified DAP and DDP rates shall be established for air by four weight bands:
    - <500 KG;
    - 501 KG - 1000 KG;
    - 1001 KG - 3000 KG;
    - 3001 KG - 5000 KG

  The modified DAP and DDP ocean rates shall also be established for fixed container rates (full 40' reefer container rate).

  For deliveries from the VMS warehouses to the nine countries in Southern Africa (detailed in annex 4), VMS partners shall be required to offer rates for temperature controlled full truck load that shall be fixed for 12-month period, December 2024 to November 2025.

  New D-Term Lane Rate Requirements. For Ocean and Air Lane rates to the ten D-Term countries, suppliers shall be required to identify and breakdown their offered lane rates into three components:
    - Door to Port (Manufacturing site to preferred port of departure)
    - Port to Port
    - Port to Door rates (Inclusive of temperature-controlled trucks, clearing costs, procurement of a minimum five free days in country, and local delivery)

  D-Term Suppliers shall also be required to procure a minimum number of "free days" secured by country and specify any country specific variable import fees that are not part of the proposed lane rate (and that the D-term supplier proposes is covered as a pass-through cost).

  GHSC-PSM shall review the offered lane rates against supplier's previously offered lane rates to GHSC-PSM, compare them to the prevailing market rates and compare them to the relative

bids received through the RFP to determine them fair and reasonable. GHSC-PSM intends to establish rates for a lane only when supplier's offered rates are deemed to be fair and reasonable. Through the review process GHSC-PSM may also request suppliers to submit at least three quotes to support the bids submitted to PSM. Suppliers must describe their methodology for obtaining fair and reasonable prices when selecting their 3PLs (competition, due diligence, etc.).

GHSC-PSM shall allow eligible D-Term suppliers to submit revised D-Term Lane rates for the follow-on period December 2025 to November 2026 in a separate FY26 RFP process. GHSC-PSM shall again review the offered lane rates against supplier's previously offered lane rates to GHSC-PSM, in comparison to the prevailing market rates and the relative bids received through the RFP. GHSC-PSM shall only accept and establish the revised lane rates if they are determined to be fair and reasonable. GHSC-PSM maintains the right to extend or revoke the validity of non-TLD ARV supplier allocations during the FY26 period based on the determination of fairness and reasonableness. Any lane rate deemed unreasonable shall result in revocation of non-TLD allocation awards for the follow-on period.

Note: Suppliers eligible to deliver ARVs under DAP or DDP incoterms shall receive a competitive advantage over those who are not.

- **Sourcing TLD through Annual Global Allocation from Strategic partners.** GHSC-PSM intends to continue to allocate 80% of the FY25 estimated global demand to a maximum of five (5) strategic TLD partners (excluding demand from Southern African region reserved for VMS). Awarded suppliers shall be established as TLD global suppliers for FY25. Based on the evaluation outcome, successful partners will be awarded a target market share percentage of the estimated demand. TLD Suppliers are required to maintain eligibility within the D-Term program (by GHSC-QA) and offer a minimum 36-month shelf-life product as a pre-requisite for award allocations within this category. GHSC-PSM shall not be responsible to award TLD business should estimate TLD demand not materialize during the period.

- **Sourcing TLD through the VMS program**. GHSC-PSM implemented the Southern Africa VMS program in March 2023 with three eligible TLD suppliers. The original period of performance for the program was November 2022 to November 2024. Operationalizing the VMS program required regulatory reforms in the region and only recently have Southern African countries begun to consider the benefits and opportunities for sourcing TLD positioned regionally. GHSC-PSM and USAID view the VMS program to be a cornerstone program to address certain in-country supply chain challenges for countries within the region. Because of these factors, GHSC-PSM intends to extend the VMS program with existing eligible TLD suppliers for an additional two years (December 2024 – November 2026).

  GHSC-PSM is considering procuring 80% of FY25 TLD demand materializing from the Southern African region from the established VMS partners (refer Annex 4 for list of countries in the region). VMS partners may be awarded a market share percentage of the estimated TLD demand for FY25, based on the evaluation outcome of the Global RFP. VMS suppliers are required to maintain D-TERM eligibility and VMS warehouse eligibility from GHSC-QA as a pre-requisite for award allocations within this category and offer fixed lane rates that are

determined to be fair and reasonable. GHSC-PSM shall review the offered lane rates based against supplier's previously offered lane rates to GHSC-PSM, in comparison to the prevailing market rates and the relative bids received through the RFP.

- **Electronic Data Interchange (EDI)**. GHSC-PSM has prioritized a strategy to begin using GS1 XML and electronic data interchange (EDI) for transactions with its supply partners. Negotiations are ongoing with an independent third-party EDI provider and GHSC-PSM expects to be able to communicate EDI implementation timelines within the Global RFP. ARV suppliers offering TLD within their response to the Global RFP, including VMS suppliers, shall be required to commit to implementing and transacting via GS1 XML-based EDI in FY25, although GHSC-PSM is targeting to begin transacting in FY24. GHSC-PSM shall maintain the right to amend TLD award allocations should TLD suppliers fail to comply.

Global RFP Sourcing Timelines. Below are key milestones and tentative dates planned for the Global RFP:

Release Pre-solicitation Notification	**17-May-24**
Release of GHSC-QA RFP for Product Eligibility and DDP/DAP Eligibility determination	21-May-2024
Close of GHSC-QA RFP for DDP/DAP Eligibility determination	14-Jun-2024
Close of GHSC-QA RFP for Product Eligibility	19-Jun-2024
ARV Supplier Conference (Virtual)	Week of 17th Jun
Release of GHSC-PSM Global RFP	28-Jun-2024
Deadline for submission of suppliers' questions on GHSC-PSM Global RFP	5-Jul-2024
Deadline for GHSC-PSM to respond to submitted questions/clarifications from suppliers	12-Jul-2024
Close of GHSC-PSM Global RFP	29-Jul-2024
Estimated Sub-contract Execution	15-Nov-2024

The dates above are tentative and may be modified at the sole discretion of Chemonics. Chemonics shall share updates as dates become finalized.

SECTION 4: QUALITY ASSURANCE (QA) REQUIREMENTS FOR GLOBAL RFP

1. **Meeting Product Eligibility QA Requirements:**

   Only product/presentations that are outlined in Annex 2 and Annex 3 of this document, and are US FDA approved or tentatively approved (NDA/ANDA) shall be considered eligible for procurement.

   All new offerors and existing suppliers are requested to follow the **Instructions for completing Finished Pharmaceutical Product Questionnaire (Questionnaire): Abbreviated version** attached to this notification (Annex 5) to help ensure a successful submission of the Questionnaire for consideration.

2. **DAP/DDP Eligibility QA Requirements:**

Suppliers offering ARVs with DAP/DDP incoterms are required to demonstrate that they, and their partners, have the experience, internal processes, and adequate quality assurance (QA) oversight to maintain product integrity while product is within their chain of custody, and including while the products are in transit between the manufacturer and the recipient. If health commodities are stored at a secondary facility or warehouse closer to a port or between manufacturing sites prior to export, offerors should have internal procedures that extend oversight of product integrity to these locations as well.

Key aspects of the quality management systems (QMSs) of the supplier and the supplier's partners that may determine eligibility and shall be evaluated include:

- Selecting, vetting, and monitoring 3PLs and 4PLs (and staging locations such as secondary facilities or warehouses) to ensure that product integrity is maintained while the product is in their custody.
- Managing and reporting product quality incidents (e.g., temperature excursions) and recalls, including the role of all corresponding 3PLs (and staging locations such as secondary facilities or warehouses) in ensuring product integrity is maintained while the product is in their custody.
- An overview of key performance indicators (KPIs) used by the supplier to monitor and manage performance.

Suppliers are requested to follow the **Instructions for Completing D-Terms Technical Questionnaire** attached to this notification (Annex 6) to help ensure a successful submission for consideration.

GHSC-PSM, on behalf of GHSC-QA, intends to release the GHSC-QA RFP by 21st May 2024, that shall cover both product eligibility determination and DDP/DAP eligibility determination. Based on the responses to GHSC-QA RFP, GHSC-QA will provide GHSC-PSM with evaluation scoring for eligible suppliers and the scoring shall be included as part of the overall evaluation criteria for the Global ARV RFP.

Annex 1: Target D-Term Countries List

Democratic Republic of the Congo
Eswatini
Haiti
Kenya
Mozambique
Nigeria
Tanzania
Uganda
Zambia
Zimbabwe

Annex 2: Potential ARVs planned to be sourced through annual allocation process.

Abacavir/Lamivudine 120/60 mg Dispersible Tablet, 30 Tablets
Abacavir/Lamivudine 600/300 mg Tablet, 30 Tablets
Atazanavir/Ritonavir 300/100 mg Tablet, 30 Tablets
Darunavir 150 mg Tablet, 240 Tablets
Darunavir 75 mg Tablet, 480 Tablets
Darunavir 600 mg Tablet, 60 Tablets
Darunavir/Ritonavir 400/50 mg, 60 Tablets
Dolutegravir 10 mg Scored Dispersible Tablet, 90 Tablets
Dolutegravir 50 mg Tablet, 30 Tablets
Dolutegravir 50 mg Tablet, 90 Tablets
Dolutegravir/Lamivudine/Abacavir 5/30/60 mg Dispersible Tablet, 180 Tablets
Dolutegravir/Lamivudine/Abacavir 5/30/60 mg Dispersible Tablet, 90 Tablets
Dolutegravir/Lamivudine/Tenofovir DF (TLD) 50/300/300 mg Tablet, 180 Tablets
Dolutegravir/Lamivudine/Tenofovir DF (TLD) 50/300/300 mg Tablet, 90 Tablets
Efavirenz/Lamivudine/Tenofovir DF (TLE400) 400/300/300 mg Tablet, 90 Tablets
Emtricitabine/Tenofovir DF 200/300 mg Tablet, 30 Tablets
Lamivudine 10 mg/mL Solution w/ Syringe, 240 mL
Lamivudine 150 mg Tablet, 60 Tablets
Lamivudine/Tenofovir DF 300/300 mg Tablet, 30 Tablets
Lamivudine/Zidovudine 150/300 mg Tablet, 60 Tablets
Lamivudine/Zidovudine 30/60 mg Dispersible Tablet, 60 Tablets
Nevirapine 10 mg/mL Suspension w/ Syringe, 100 mL
Nevirapine 10 mg/mL Suspension, 100 mL
Nevirapine 50 mg Dispersible Tablet, 60 Tablets
Raltegravir 100 mg Granules for Suspension, 60 Sachets
Ritonavir 100 mg Film Coated Tablet, 60 Tablets
Ritonavir 100 mg Tablet, 60 Tablets
Ritonavir 25 mg Tablet, 30 Tablets
Zidovudine 10 mg/mL Solution w/ Syringe, 240 mL
Zidovudine 10 mg/mL Solution, 240 mL

Annex 3: Potential ARVs planned to be sourced through open competition.

Dolutegravir/Emtricitabine/Tenofovir AF (TAFED) 50/200/25 mg Tablet, 30 Tablets
Dolutegravir/Emtricitabine/Tenofovir AF (TAFED) 50/200/25 mg Tablet, 90 Tablets
Dolutegravir/Lamivudine/Abacavir (ALD) 50/300/600 mg Tablet, 30 Tablets
Dolutegravir/Lamivudine/Tenofovir AF (TAFLD) 50/300/25 mg Tablet, 30 Tablets
Dolutegravir/Lamivudine/Tenofovir AF (TAFLD) 50/300/25 mg Tablet, 90 Tablets
Dolutegravir/Lamivudine/Tenofovir DF (TLD) 50/300/300 mg Tablet, 30 Tablets
Lopinavir 40/10 mg, Granules for Suspension, 120 Sachets
Tenofovir 300 mg Tablet, 30 Tablets

Annex 4: Southern African Countries

Angola
Botswana
Eswatini
Lesotho
Malawi
Mozambique
Namibia
Zambia
Zimbabwe

Annex 5

Instructions for completing Finished Pharmaceutical Product Questionnaire: Abbreviated

Only offers of products outlined in the RFP and meeting eligibility criteria outlined in the RFP will be considered eligible for review. FHI 360 (through the U.S. Agency for International Development [USAID] Global Health Supply Chain-Quality Assurance Program [GHSC-QA] will provide GHSC-PSM with a quality assurance (QA) score that will be included as part of the overall offer evaluation criteria. In Ivalua, offerors are required to confirm that they have read and understood the instructions for creating a GHSC- QA Technical Questionnaire Submission and confirm that they have uploaded the required documentation to the GHSC-QA website in accordance with *ALL.WI.GEN-101.01 Instructions for Creating and Submitting Technical Documentation to FHI 360*.

Carefully read the instructions below to help ensure an accurate completion of *ALL.APP.FPP-107.02: Finished Pharmaceutical Product Questionnaire: Abbreviated*.

Offerors of products/manufacturing sites/presentations **not evaluated**[2] by GHSC-QA: Complete *ALL.APP.FPP-107.02 Finished Pharmaceutical Product Questionnaire- Abbreviated* and provide the information requested.

Eligible suppliers of products/manufacturing sites/presentations **evaluated** by GHSC-QA **and whose previously submitted technical documentation remains valid** and **that do not have updates to report**, are requested to complete the following sections of *ALL.APP.FPP-107.02 Finished Pharmaceutical Product Questionnaire- Abbreviated* for each offered product/manufacturing site and product presentation:

Section 1.0 Applicant Information
Section 2.0 Product Identification
Section 7.0 Product Quality Review
Section 10.0 Authorization and Commitment

Eligible suppliers that have **technical updates** to report are requested to complete the **relevant** sections in *ALL.APP.FPP-107.02 Finished Pharmaceutical Product Questionnaire- Abbreviated* to provide updated information and documentation (e.g., updated FPP Specifications and Analytical Methods, nitrosamine risk assessment; updated FPP packaging, labelling, updated stability data to support FPP Shelf-life or storage conditions, updated API information). The following sections are required to be completed regardless of the technical update incorporated:

Sections 1.0 Applicant Information,
Section 2.0 Product Identification,
Section 7.0 Product Quality Review
Section 10.0 Authorization and Commitment

2 Technical documentation for offers previously evaluated but determined not to be eligible may be submitted as a new offer if the product meets the requirements established in the solicitation.

Offers that do not include the appropriate authorization and commitment signatures may not be considered for review.

The table below summarizes the required sections to be completed by the supplier in *ALL.APP.FPP-107.02: Finished Pharmaceutical Product Questionnaire: Abbreviated* for GHSC-QA evaluation of product eligibility.

Eligibility QA Status	**Questionnaire Sections to be completed by supplier:**
New products / manufacturing sites/ presentations **not evaluated**[2] by GHSC-QA	All sections: 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0
Currently eligible products / manufacturing sites/ presentations **without** technical updates to report.	1.0, 2.0, 7.0, 10.0
Currently eligible products / manufacturing sites/ presentations **with** technical updates to report.	1.0, 2.0, 7.0, 10.0 + any other section relevant to the update

Annex 6

Instructions for Completing D-Terms Technical Questionnaire

Only delivery at place (DAP) and delivery duty paid (DDP) offers meeting the criteria outlined in the RFP will be considered eligible for review. FHI 360 (through the U.S. Agency for International Development [USAID] Global Health Supply Chain-Quality Assurance Program [GHSC-QA] will provide GHSC-PSM with a quality assurance (QA) score that will be included as part of the overall offer evaluation criteria. In Ivalua, offerors are required to confirm that they have read and understood the instructions for creating a GHSC-QA Technical Questionnaire Submission and confirm that they have uploaded the required documentation to the GHSC-QA website in accordance with *ALL.WI.GEN-101.00 Instructions for Creating and Submitting Technical Documentation to FHI 360*.

Carefully read the instructions below to help ensure and accurate completion of *ALL.APP.GEN-226.01 Technical Questionnaire Delivery at Place (DAP) and Delivery Duty Paid (DDP) Incoterms and Vendor Managed Solutions (VMS).*

New offerors (including currently not eligible[3]) of DAP and DDP shipments shall complete Section 2.0 OFFEROR: QUALITY ASSURANCE OVERSIGHT FOR CONTRACTED LOGISTICS PROVIDER (3PL) AND/OR WAREHOUSE PROVIDER (VMS) AND Section 3.0 DAP AND DDP INCOTERM DELIVERY, **including all the subsections, and include the appropriate attachments as requested.**

Currently eligible offerors of DAP and DDP shipments **that have updated their QA oversight procedures for DDP and DAP services** since becoming eligible shall complete the relevant sections Section 2.0 OFFEROR: QUALITY ASSURANCE OVERSIGHT FOR CONTRACTED LOGISTICS PROVIDER (3PL) AND/OR WAREHOUSE PROVIDER (VMS) including the subsections related to the updates and include the appropriate attachments as requested.

Currently eligible offerors of DAP and DDP shipments that **have updated the currently eligible third-party logistics providers (3PLs)** shall complete the relevant sections in Section 3.0 DAP and DDP INCOTERM DELIVERY, 3.1 Subcontracted Third-Party Logistics Provider (3PL) related to the updates and include the appropriate attachments as requested.

Currently eligible offerors of DAP and DDP shipments that are **interested in adding additional 3PLs** or **re-evaluation of 3PLs previously determined to be ineligible** shall complete Section 3.0 DAP and DDP INCOTERM DELIVERY and 3.1 Subcontracted Third-Party Logistics Provider (3PLs), in its entirety, and include the appropriate attachments as requested.

In addition to the appropriate sections above**, all offerors** shall complete Section 1.0 APPLICANT INFORMATION and Section 5.0 AUTHORIZATION AND COMMITMENT. When no updates are required (**previously submitted technical documentation remains valid with no updates),** the offeror shall add a statement to the authorization and commitment specifying that "no updates are required." **_Offers that do not include the appropriate applicant information and authorization and commitment signatures may not be considered for review**.
This RFQ is specific for DAP and DDP shipments, so **all offerors** are cautioned **not to complete**

[3] Suppliers that have not received a DAP/DDP eligibility notification letter from GHSC-QA.

Section 4.0 Vendor Managed Services (VMS) and its associated subsections as these are not relevant to the current RFP.

The table below summarizes the required sections to be completed by the supplier in *ALL.APP.GEN-226.01 Technical Questionnaire Delivery at Place (DAP) and Delivery Duty Paid (DDP) Incoterms and Vendor Managed Solutions (VMS)* for GHSC-QA evaluation for DAP/DDP eligibility.

DAP/DDP QA Status	**Questionnaire Sections to be completed by supplier:**
New offerors (including currently not eligible for DAP/DDP)	1.0, 2.0, 3.0, and 5.0
Currently eligible DAP/DDP supplier with updates to oversight procedures of existing 3PLs	1.0, 2.0 (as needed), and 5.0
Currently eligible DAP/DDP supplier with updated information on currently eligible 3PLs	1.0, 3.0 (as needed) and (3.1 for updates to each relevant 3PL), and 5.0
Currently eligible DAP/DDP supplier adding additional 3PLs or re-evaluation of previously ineligible 3PLs	1.0, 3.0 (ass needed) (3.1 for each new 3 PL), and 5.0